The Claim
GLP-1 receptor positron emission tomography (PET) imaging may allow for noninvasive differentiation between beta-cell loss and beta-cell dysfunction in individuals with type 1 or type 2 diabetes mellitus, potentially serving as a tool for disease stratification and monitoring.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A special kind of body scan might help doctors tell the difference between when insulin-making cells in the pancreas are gone versus just not working right — without needing surgery — which could help better manage diabetes.
See the scientific wording
GLP-1 receptor PET imaging may enable noninvasive differentiation between β-cell loss and β-cell dysfunction in individuals with type 1 or type 2 diabetes mellitus, offering a potential tool for disease stratification and monitoring.
What the research says
1 studyStudy: Clinical applications of GLP-1 receptor–targeted PET imaging: A disease-oriented review
The study looks at a special scan that can show how well insulin-making cells in the pancreas are working. It says the scan can tell the difference between when those cells are missing or just not working right in people with diabetes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.